Maximizing Outcomes: Synchronizing Liraglutide And Tailored Exercise In Weight Loss - A Case Study

HISTORY: Mr. X, a 51-year-old male with a 20-year history of obesity, presented after multiple failed weight loss attempts through diet and exercise. He expressed growing concern over his health, citing fatigue, joint pain, and difficulty maintaining physical activity due to his weight. PHYSICAL EXAMINATION: Mr. X exhibited a BMI of 36.2 kg/m2, with prominent central adiposity and a waist circumference indicative of increased cardiovascular risk. His blood pressure and heart rate were within normal limits, with no musculoskeletal contraindications to exercise. DIFFERENTIAL DIAGNOSIS: The differential diagnosis included: 1. Primary Obesity 2. Metabolic Syndrome 3. Hypothyroidism 4. Insulin Resistance 5. Type 2 Diabetes Mellitus TEST AND RESULTS: A comprehensive metabolic panel revealed normal thyroid and glucose levels, ruling out hypothyroidism and Type 2 Diabetes. Exercise testing showed: • VT VO2: 17.6 ml/kg/min • VT HR: 114 bpm • VO2 Max: 36.8 ml/kg/min • Max HR: 177 bpm Body composition and anthropometric measures, including weekly neck, arm, waist, and hip circumferences, were recorded to track progress. FINAL WORKING DIAGNOSIS: The final diagnosis was primary obesity complicated by central adiposity and functional limitations. TREATMENT AND OUTCOMES: Mr. X began on an incremental protocol of liraglutide (Saxenda), starting at 0.6 mg daily and gradually increasing to the maximum dose of 3 mg daily over several weeks. This pharmacological approach was combined with a tailored exercise regimen consisting of 300 minutes per week, which included aerobic exercise, strength training, and HIIT. Over 17 weeks, Mr. X achieved a remarkable total weight loss of 29.5 kg, which represented 32.5% of his initial body weight, far exceeding the typical 7-10% weight loss expected from liraglutide therapy alone. His BMI dropped from 36.2 kg/m2 to 26.1 kg/m2. Waist circumference and overall fat mass significantly decreased. He showed enhanced cardiovascular endurance, improved musculoskeletal strength, and maintained consistent engagement in the exercise program without complications. This case highlights the synergy between pharmacological therapy and personalized exercise in achieving substantial, sustainable weight loss and improving overall fitness. Supported by: No specific grant funding was utilized for this research. Additionally, no external funding sources or artificial intelligence assistance were involved in the analysis or conclusions of the study.